Evidence map›Paper›PMID 39011666›Full record

ArticleJournal of cellular and molecular medicine2024

Deciphering the tumour microenvironment of clear cell renal cell carcinoma: Prognostic insights from programmed death genes using machine learning.

Hongtao Tu, Qingwen Hu, Yuying Ma, Jinbang Huang, Honghao Luo, Lai Jiang, Shengke Zhang, Chenglu Jiang, Haotian Lai, Jie Liu and 6 more

Abstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. TSPAN4Frontiers in immunology · 2025
    Article
  4. Article
  5. CSF2 polarized neutrophils and invaded renal cancer cellsOpen medicine (Warsaw, Poland) · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Integrating multi-omics techniques andFrontiers in immunology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Hongtao TuDepartment of Urology, Dazhou Central Hospital, Dazhou, Sichuan, China.
Qingwen HuSchool of Clinical Medicine, The Affiliated Hospital, Southwest Medical University, Luzhou, China.
Yuying MaThree Gorges Hospital, Chongqing University, Chongqing, China.
Jinbang HuangSchool of Clinical Medicine, The Affiliated Hospital, Southwest Medical University, Luzhou, China.
Honghao LuoDepartment of Radiology, Xichong People's Hospital, Nanchong, China.
Lai JiangSchool of Clinical Medicine, The Affiliated Hospital, Southwest Medical University, Luzhou, China.
Shengke ZhangSchool of Clinical Medicine, The Affiliated Hospital, Southwest Medical University, Luzhou, China.
Chenglu JiangSchool of Clinical Medicine, The Affiliated Hospital, Southwest Medical University, Luzhou, China.
Haotian LaiSchool of Clinical Medicine, The Affiliated Hospital, Southwest Medical University, Luzhou, China.
Jie LiuSchool of Clinical Medicine, The Affiliated Hospital, Southwest Medical University, Luzhou, China.
Jianyou ChenDepartment of Urology, Dazhou Integrated Traditional Chinese Medicine and Western Medicine Hospital, Dazhou, Sichuan, China.
Liwei GuoDepartment of Urology, The Dazhu County People's Hospital, Dazhou, China.
Guanhu YangDepartment of Specialty Medicine, Ohio University, Athens, Ohio, USA.
Ke XuDepartment of Oncology, Chongqing General Hospital, Chongqing University, Chongqing, China.
Hao ChiSchool of Clinical Medicine, The Affiliated Hospital, Southwest Medical University, Luzhou, China.ORCID 0000-0002-5210-0770
Haiqing ChenSchool of Clinical Medicine, The Affiliated Hospital, Southwest Medical University, Luzhou, China.

Funding

Dazhu Science and Technology Bureau project 2022NCG0013Dazhu Science and Technology Bureau project 2022NCG0014
6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC), a prevalent kidney cancer form characterised by its invasiveness and heterogeneity, presents challenges in late-stage prognosis and treatment outcomes. Programmed cell death mechanisms, crucial in eliminating cancer cells, offer substantial insights into malignant tumour diagnosis, treatment and prognosis. This study aims to provide a model based on 15 types of Programmed Cell Death-Related Genes (PCDRGs) for evaluating immune microenvironment and prognosis in ccRCC patients. ccRCC patients from the TCGA and arrayexpress cohorts were grouped based on PCDRGs. A combination model using Lasso and SuperPC was constructed to identify prognostic gene features. The arrayexpress cohort validated the model, confirming its robustness. Immune microenvironment analysis, facilitated by PCDRGs, employed various methods, including CIBERSORT. Drug sensitivity analysis guided clinical treatment decisions. Single-cell data enabled Programmed Cell Death-Related scoring, subsequent pseudo-temporal and cell-cell communication analyses. A PCDRGs signature was established using TCGA-KIRC data. External validation in the arrayexpress cohort underscored the model's superiority over traditional clinical features. Furthermore, our single-cell analysis unveiled the roles of PCDRG-based single-cell subgroups in ccRCC, both in pseudo-temporal progression and intercellular communication. Finally, we performed CCK-8 assay and other experiments to investigate csf2. In conclusion, these findings reveal that csf2 inhibit the growth, infiltration and movement of cells associated with renal clear cell carcinoma. This study introduces a PCDRGs prognostic model benefiting ccRCC patients while shedding light on the pivotal role of programmed cell death genes in shaping the immune microenvironment of ccRCC patients.

Indexed as

Carcinoma, Renal CellGene Expression Regulation, NeoplasticKidney NeoplasmsMachine LearningTumor MicroenvironmentApoptosisBiomarkers, TumorGene Expression ProfilingHumansPrognosisSingle-Cell AnalysisBiomarkers, Tumorcancer biomarkersdrug screenmachine learningprognosisprogrammed cell deathtumour microenvironmenturologic tumours

Identifiers

PMID39011666
PMCPMC11249822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.